Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Key Takeaway: Acadia Pharmaceuticals presented new data from the Phase 2 RADIANT trial for remlifanserin at the 2026 CTAD conference. The findings support the drug's efficacy in treating hallucinations and delusions in Alzheimer's disease psychosis. This builds on previously announced topline results, indicating a promising treatment avenue.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presented additional data from Phase 2 RADIANT trial.
  • Showed consistent efficacy signal for remlifanserin.
  • Highlighted potential for treating Alzheimer's disease psychosis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
6.4%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once

Frequently Asked Questions

What is the RADIANT trial?

The RADIANT trial evaluates remlifanserin for treating Alzheimer's disease psychosis.

What were the results presented at CTAD?

New analyses showed a consistent efficacy signal for remlifanserin.

Where was the data presented?

The data was presented at the 2026 CTAD conference in Boston.

What condition does remlifanserin target?

Remlifanserin targets hallucinations and delusions in Alzheimer's disease psychosis.

Last updated: Nov 17, 2026